Your browser doesn't support javascript.
loading
Treatment of metastatic squamous cell carcinoma arising in sacrococcygeal pilonidal sinus: a case report series.
Soria Rivas, Ainara; Bea-Ardebol, Sonia; Vida Navas, Elena; Muñoz-Arrones, Óscar M; Cabañas-Montero, Luis Jacobo; Mena-Mateos, Antonio; López-Campos, Fernando; Corral Moreno, Sara; Pérez-Muñoz, Israel; González Lizan, Fausto; Sanz Pascual, María; Serrano Domingo, Juan Jose.
Affiliation
  • Soria Rivas A; Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Bea-Ardebol S; Dermatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Vida Navas E; Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Muñoz-Arrones ÓM; Dermatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Cabañas-Montero LJ; Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Mena-Mateos A; Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • López-Campos F; Radiation Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Corral Moreno S; Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Pérez-Muñoz I; Orthopedics and Orthopedic Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • González Lizan F; Orthopedics and Orthopedic Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Sanz Pascual M; Orthopedics and Orthopedic Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Serrano Domingo JJ; Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Front Med (Lausanne) ; 10: 1248894, 2023.
Article in En | MEDLINE | ID: mdl-37780565
Background: Squamous cell carcinoma (SCC) arising in a sacrococcygeal pilonidal sinus is rare, with cases of metastatic disease being even rarer. Among published cases, almost none have reported on systemic treatment. Objective: This disease has a poorer prognosis than other forms of cutaneous SCC; therefore, our objective is to shed some light on the treatment of metastatic disease. Methods: We present a series of nine cases treated at a single center, four of whom received systemic treatment. Additionally, other previously reported cases of metastatic disease are included in an attempt to draw stronger conclusions. Results: Four patients were treated under several treatment regimens, with a median progression-free survival of only 2 months and two instances of partial response (18%). The best result was achieved with cemiplimab. Across all the cases, there was a trend toward a benefit of the use of systemic treatment (HR 0.41, 95% CI 0.15-1.12, p = 0.083; median overall survival 13 vs. 8 months). Limitations: Limitations include the significant lack of information on previously published cases and the extremely heterogeneous nature of the existing information. Conclusion: The initial systemic treatment should be an anti-PD-1, as with other SCCs. After progression on anti-PD-1, there is no strong evidence to support the recommendation of a specific treatment or sequence: options include cetuximab and/or chemotherapy (platinum, paclitaxel, 5-fluorouracyl).
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies Language: En Journal: Front Med (Lausanne) Year: 2023 Document type: Article Affiliation country: Spain Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies Language: En Journal: Front Med (Lausanne) Year: 2023 Document type: Article Affiliation country: Spain Country of publication: Switzerland